Search Results - "CANETTA, Renzo"

The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: the Bristol-Myers Squibb experience by Berman, David, Korman, Alan, Peck, Ronald, Feltquate, David, Lonberg, Nils, Canetta, Renzo

“…The discovery and increased understanding of the complex interactions regulating the immune system have contributed to the pharmacologic activation of…”
Get full text

Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy by Hoos, Axel, Ibrahim, Ramy, Korman, Alan, Abdallah, Kald, Berman, David, Shahabi, Vafa, Chin, Kevin, Canetta, Renzo, Humphrey, Rachel

“…Identification of cytotoxic T-lymphocyte antigen-4 (CTLA-4) as a key negative regulator of T-cell activity led to development of the fully human, monoclonal…”
Get full text

Development of other microtubule-stabilizer families: the epothilones and their derivatives by Brogdon, Cynthia F, Lee, Francis Y, Canetta, Renzo M

“…Chemotherapy is the mainstay of treatment for numerous cancer types, but resistance to chemotherapy remains a major clinical issue and is one of the driving…”
Get full text

Initial Paclitaxel Improves Outcome Compared With CMFP Combination Chemotherapy as Front-Line Therapy in Untreated Metastatic Breast Cancer by James F. Bishop, Joanna Dewar, Guy C. Toner, Jennifer Smith, Martin H.N. Tattersall, Ian N. Olver, Stephen Ackland, Ian Kennedy, David Goldstein, Howard Gurney, Euan Walpole, John Levi, Jennifer Stephenson, Renzo Canetta, for the Taxol Investigational Trials Group, Australia/New Zealand

“…To determine the place of single-agent paclitaxel compared with nonanthracycline combination chemotherapy as front-line therapy in metastatic breast cancer…”
Get full text

Global Development of Anticancer Therapies for Rare Cancers, Pediatric Cancers, and Molecular Subtypes of Common Cancers by Lyerly, H Kim, Ren, Jun, Canetta, Renzo, Kim, Gi Hyun, Nagai, Sumimasa, Yamaguchi, Tomohiro, Hatogai, Ken, Katayama, Hiroshi, Da Rocha Dias, Silvy, McManus, Daniel, Soltys, Kathy, Yang, Zhimin, Olopade, Olufumilayo, Goodman, Nancy, Reaman, Greg, Gross, Thomas

“…Advances in genetic sequencing and other diagnostic technologies have enabled the use of precision medicine in clinical cancer care, as well as the development…”
Get full text

Accelerating Cancer Therapy Development: The Importance of Combination Strategies and Collaboration. Summary of an Institute of Medicine Workshop by LORUSSO, Patricia M, CANETTA, Renzo, WAGNER, John A, BALOGH, Erin P, NASS, Sharyl J, BOERNER, Scott A, HOHNEKER, John

“…Cancer cells contain multiple genetic changes in cell signaling pathways that drive abnormal cell survival, proliferation, invasion, and metastasis…”
Get full text

Expanding Public‐Private Collaborations to Enhance Cancer Drug Development: A Report of the Institute of Medicine's Workshop Series, “Implementing a National Cancer Clinical Trials System for the 21st Century” by Bertagnolli, Monica M., Canetta, Renzo, Nass, Sharyl J.

“…Since their inception in the 1950s, the National Cancer Institute‐funded cancer cooperative groups have been important contributors to cancer clinical and…”
Get full text

Selection of Response Criteria for Clinical Trials of Sarcoma Treatment by Schuetze, Scott M., Baker, Laurence H., Benjamin, Robert S., Canetta, Renzo

“…Soft tissue sarcomas are a heterogeneous group of malignancies arising from mesenchymal tissues. A large number of new therapies are being evaluated in…”
Get full text

Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology by Salgado, Roberto, Solit, David B., Rimm, David L., Bogaerts, Jan, Canetta, Renzo, Lively, Tracy, Lyerly, Kim, Span, Paul N., Bateman-House, Alison, Makady, Amr, Bergmann, L., Nagai, Sumimasa, Smith, Chris, Robson, Mark, Savage, Mary, Voest, Emile, Sweeney, Christopher, Lambin, Philippe, Thomas, Marlene, Harris, Lyndsay, Lacombe, Denis, Massard, Chistophe, Bernards, Rene, Bogaerts, Jan, Canetta, Renzo, Sullivan, Richard, Tejpar, Sabine, Lukinova, Nina, Lyerly, Herbert K., Moore, Helen, Smith, Malcolm A., Yee, Laura, DuBois, Ray, Hahn, William C., Janne, Pasi, Solit, David B., Willman, Cheryl L., Rimm, David, Bateman-House, Alison, Makady, Amr, Bergmann, Lothar, Nagai, Sumimasa, Thomas, Marlene, Cree, Ian A., Hegde, Priti, Hopper, Shirley, Smith, Chris, Robson, Marc, Savage, Mary, Voest, Emile, Sweeney, Christopher, Ingelman-Sundberg, Magnus, Nichols, Gwen, Maignen, Francois, Besse, Benjamin, Swierzewski, Rafal, Lambin, Philippe, Kiermaier, Astrid, Lacombe, Denis, Lively, Tracy, Massard, Christophe, Caliguri, Michael, Velculescu, Victor, Foggi, Paolo, Hahn, Willem C., Lukinova, Nina, Salgado, Roberto, Golfinopoulos, Vassilis

“…Academic, industry, regulatory leaders and patient advocates in cancer clinical research met in November 2018 at the Innovation and Biomarkers in Cancer Drug…”
Get full text

Long-Term Follow-Up of Didanosine Administered Orally Twice Daily to Patients with Advanced Human Immunodeficiency Virus Infection and Hematologic Intolerance of Zidovudine by Allan, J. Davis, Connolly, Kevin J., Fitch, Helen, Jackson-Pope, Lenore, McLaren, Colin, Canetta, Renzo, Groopman, Jerome E.

“…This phase 1 trial was conducted to evaluate the safety and tolerance of didanosine (ddI) in subjects with AIDS or AIDS-related complex (ARC) who previously…”
Get full text

Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy : Immunologic checkpoints for cancer treatment: from scientific rationale to clinical application by HOOS, Axel, IBRAHIM, Ramy, KORMAN, Alan, ABDOLLAH, Kald, BERMAN, David, SHAHABI, Vafa, CHIN, Kevin, CANETTA, Renzo, HUMPHREY, Rachel

Get full text

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion by Eisenhauer, E A, ten Bokkel Huinink, W W, Swenerton, K D, Gianni, L, Myles, J, van der Burg, M E, Kerr, I, Vermorken, J B, Buser, K, Colombo, N

“…Taxol (paclitaxel; Bristol-Myers Squibb, Wallingford, CT) is a new anticancer agent with activity in a number of human tumors, including epithelial ovarian…”
Get more information

Nuove Frontiere Di Trattamento in Oncologia by Canetta, Renzo

Get full text

Promising new developments in cancer chemotherapy by FERRANTE, K, WINOGRAD, B, CANETTA, R

“…The positive impact on survival of traditional chemotherapeutic agents has renewed interest in developing newer cytotoxic agents and orally active compounds…”
Get full text

An audit strategy for time-to-event outcomes measured with error: Application to five randomized controlled trials in oncology by Dodd, Lori E, Korn, Edward L, Freidlin, Boris, Gu, Wenjuan, Abrams, Jeffrey S, Bushnell, William D, Canetta, Renzo, Doroshow, James H, Gray, Robert J, Sridhara, Rajeshwari

“…Background Measurement error in time-to-event end points complicates interpretation of treatment effects in clinical trials. Non-differential measurement error…”
Get full text

Taxol: the first of the taxanes, an important new class of antitumor agents by Rowinsky, E K, Onetto, N, Canetta, R M, Arbuck, S G

“…The taxanes represent the first class of antimicrotubule agents with a new mechanism of cytotoxic action since the introduction of the vinca alkaloids several…”
Get more information

Uracil-ftorafur: an oral fluoropyrimidine active in colorectal cancer by Sulkes, A, Benner, S E, Canetta, R M

“…This review describes the early clinical development of uracil-ftorafur (UFT), an oral fluoropyrimidine, designed in 1978 by adding uracil to ftorafur. The…”
Get more information

Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer by Jodrell, D I, Egorin, M J, Canetta, R M, Langenberg, P, Goldbloom, E P, Burroughs, J N, Goodlow, J L, Tan, S, Wiltshaw, E

“…The study was undertaken to define the relationship between tumor response and carboplatin area under the curve (AUC) in patients with ovarian cancer; to study…”
Get more information

Apoptotic pathways of epothilone BMS 310705 by Uyar, Denise, Takigawa, Nagio, Mekhail, Tarek, Grabowski, Dale, Markman, Maurie, Lee, Francis, Canetta, Renzo, Peck, Ron, Bukowski, Ronald, Ganapathi, Ram

“…BMS 310705 is a novel water-soluble analog of epothilone B currently in phase I clinical evaluation in the treatment of malignancies such as ovarian, renal,…”
Get full text

Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer by Reichman, B S, Seidman, A D, Crown, J P, Heelan, R, Hakes, T B, Lebwohl, D E, Gilewski, T A, Surbone, A, Currie, V, Hudis, C A

“…A phase II study of Taxol (paclitaxel; Bristol-Myers Squibb Co, Princeton, NJ) as initial chemotherapy for metastatic breast cancer was conducted. Recombinant…”
Get more information